Member Info for RayPointer

But Ruck, there are 2 separate teams within Scancell.
A research team and a development team.
Are you suggesting that research should stop when development is happening?

Tommy

As I understand it, the work of getting a trial underway is performed by Sally Adam's team.

When Lindy is happy that she has a product ready to trial, the work of getting the trial underway is Sally's responsibility.
So Sally oversees the manufacture, and then conducts the toxicology tests and submits the IND or CTA.
Of course Sally will consult Lindy frequently during this pre-clinical work and indeed we have seen Lindy sorting out a manufacturing problem with Modi1.

If Lindy were to stop her normal work during this pre-clinical phase, we would not have Modi2, or the GC and the BionTech collaboration would slow and perhaps stop.

It is this division of labour between Lindy's team and Sally's team that you don't appear to have grasped.

I assume part funded by Scancell.

https://www.dur.ac.uk/study/pg/studyoptions/research/dtc/

http://www.nld-dtp.org.uk/

Here a good lecture describing what mass spectrometry is all about

https://www.ibiology.org/techniques/mass-spectrometry/

So, Lindy, having found citrullinated and homocitrullinated targets, is not content to stick at this.
She is commissioning research looking for new classes of targets using mass spectrometry.

It is likely that Adam Benham is helping in this research.
It also seems likely that this is all about making Moditope even more potent.

Funny that one of the PBP team members is at Durham

Dr Adam Benham
Associate Professor? of Molecular Biology

Country: UK
Organisation: Durham University
Discipline: Molecular biology

Who can lay a brick in less than 10 seconds.
Slap on the mortar, butter the brick then tap, tap - on with the next one

I wish I could predict SP movements

If moditope works I would say we were in Kite territory as far as value is concerned, maybe more.
Would you agree?

Kite was sold for $11.9billion about £9 billion

So assuming we have no more dilution (i.e we get a Biontech deal with enough cash to see us through trials) what SP would a £9billion MCap equate to.

Simple calculation 9000/33 x .08 = £21.81 (current MCap 33 milion)

What chance is the AIM market giving for this treble to happen = 2181/8 =272/1 (£21.81 divided by 8 pence)

i.e The market is saying that it is 272/1 for the treble of moditope working and a BionTech deal and a sale price of £9 billion

You can put your own odds on each of these 3 events and do your own calculation

1) Moditope working
2) Biontech deal with sufficient cash
3) Sale price of £9 billion given that 1) and 2) happen

I'm off out to lay a few bricks while you ponder this.

Plausible Rats
A spring clean on tiny holdings (by their standards)

Yes, I see what you mean Ivy.
I wasn't aware that so many IIs bought, albeit below notifiable levels.

Anyway, I vote we have a virtual party on the night the GC result is announced.
I am quite happy to provide the virtual drinks.

If it is Calculus 1M or so shares is not exactly a sell off.
Could be clients are selling having held for 5 years to qualify for tax relief.
Calculus could always borrow if they do not have enough cash but they may choose not to in the current uncertainty.

Sorry
The FSTE Aim all share was actually up today

Conflicting info on LSE

http://www.lse.co.uk/uk-indices.asp

http://www.lse.co.uk/indices.asp?index=IDX:AXX&indexname=ftse_aim_all-share

Ivy
They all seem to be nicely rounded numbers of shares 100k, 200k, 150K
So it may well be the case.

Mrs May is thinking of buying, so she is try to manipulate the price down as low as possible!

The FTSE AIM all share is down nearly 6%. This may explain it.
Brexit Blues!

Thanks for that Malachi

I quote from the RNS

"Using the Parsortix system, Basel was able to investigate CTC clusters both from patient blood and from animal models. The analysis of the CTC clusters led to Basel discovering key, previously unknown, epigenetic changes present in the CTC clusters making them highly effective at spreading the cancer."

"Following this discovery, the researchers investigated the potential for 2,486 compounds already approved by the FDA for a number of different indications, to cause the CTC clusters to dissociate (break up into individual cells). They found a small number of drugs with the capability to do this. Once dissociated, they found that CTC clusters (now single cells) lost their high metastatic potential."

So, as I suggested, Pastorix is being used as a diagnostic tool to find which patients would respond to this treatment. Another compound is then used to break up the CTCs and hence stop the cancer spreading.
At least in this particular initiative.

And since the identified compounds are approved for non-cancer conditions they would have to be trialled for cancer.

Yes, I would have thought this would interest big pharma and especially those owning the identified compounds.

I'm just trying to get an idea of the likely timetable from now on.
Do we know if Angle is already actively collaborating with any of the compound owners or is it too early for this?

Oh, and do we know what percentage of patients exhibit these epigenetic changes?
Is it also dependant on the type of cancer?

Sorry for the questions but it does sound very promising.

As I understand it Pastorix is a diagnostic tool used to identify patients with CTC clusters with certain epigenetic changes present.
Am I right?

The excitement comes in that Angle have identified a number of approved drugs that have the capability of breaking up CTC clusters thus making the clusters far less effective in spreading cancer.

So, Partorix diagnostics first, and if positive, use one of the identified drugs.

Presumably, the identified drugs, will still need to go through separate clinical trials for cancer since they are currently approved for non-cancer conditions only.

Posts crossed Ivy. Great minds .....

Around this time last year we had a flurry of good news items.
Be nice it history repeats

Good day today, I like a bit of sport on Sunday